<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>Chapter 03 Pharmacy Services | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/10.09.03/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/10.09.03/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|10|09|03|"/>
    <meta itemprop="doc-type" content="container" data-document=""/>
    <meta itemprop="doc-num" content="03"/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="10|09|03" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="http://regs.maryland.gov//us/md/exec/comar/10.09.03"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Chapter 03 Pharmacy Services | Library of Maryland Regulations"/>
    <meta property="og:image" content="http://regs.maryland.gov//us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/10.09.03/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/10.09.03/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10" title="Title 10 MARYLAND DEPARTMENT OF HEALTH">Title 10 MARYLAND DEPARTMENT OF HEALTH</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|09" data-search-heading="">
                  <a href="/us/md/exec/comar/10.09" title="Subtitle 09 MEDICAL CARE PROGRAMS">Subtitle 09 MEDICAL CARE PROGRAMS</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|09|03" data-search-heading="">
                  <span title="Chapter 03 Pharmacy Services">Chapter 03 Pharmacy Services</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="10|09|03">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/10.09.03">Chapter 03 Pharmacy Services</h1>
                <section class="line-group annotations">
                  <h2>Administrative History</h2>
                  <p>Effective date: February 16, 1966</p>
                  <p>Amended effective March 15, 1967; July 1, 1967; December 1, 1969; July 1, 1971; January 22, 1975 (2:2 Md. R. 86); March 18, 1975 (2:9 Md. R. 659); July 1, 1975 (2:15 Md. R. 1066); January 1, 1976 (2:29 Md. R. 1739)</p>
                  <p>Existing regulations repealed and new regulations adopted effective September 1, 1976 (3:18 Md. R. 981)</p>
                  <p>——————</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.01" title=".01 Definitions.">Regulation .01</a> amended effective June 1, 1985 (12:10 Md. R. 961); April 30, 1988 (15:8 Md. R. 1009); March 14, 1989 (16:4 Md. R. 497)</p>
                  <p>Regulations .01, .02, .04, .05A, .06, .07H, and .09A—C amended as an emergency provision effective July 2, 1979 (6:14 Md. R. 1203); expired November 10, 1979</p>
                  <p>Regulations .01, .03, .05 and .07 amended as an emergency provision effective November 15, 1988 (15:23 Md. R. 2654); emergency status expired March 13, 1989</p>
                  <p>Regulations .01, .05C, .07H, H-1 amended as an emergency provision effective October 1, 1982 (10:1 Md. R. 19); adopted permanently effective January 30, 1983 (10:1 Md. R. 29)</p>
                  <p>Regulations .01 and .07 amended as an emergency provision effective December 31, 1987 (15:2 Md. R. 117) (Emergency provisions are temporary and not printed in COMAR)</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.01" title=".01 Definitions.">.01</a>—<a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05" title=".05 Limitations.">.05</a> and .07 amended as an emergency provision effective July 1, 1995 (22:15 Md. R. 1113); amended permanently effective October 23, 1995 (22:21 Md. R. 1615)</p>
                  <p>Regulations .01, .05, and .07 amended as an emergency provision effective July 1, 1996 (23:15 Md. R. 1081); amended permanently effective December 30, 1996 (23:26 Md. R. 1860)</p>
                  <p>Regulations .01B, .05C, and .07C, H—J amended as an emergency provision effective April 1, 1991 (18:8 Md. R. 861); amended permanently effective July 8, 1991 (18:13 Md. R. 1482)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.01#B" title="">Regulation .01B</a> amended effective July 1, 1992 (19:11 Md. R. 1015)</p>
                  <p>Regulations .01B, .05C, and .07I amended as an emergency provision effective July 9, 1998 (25:16 Md. R. 1261); amended permanently effective October 19, 1998 (25:21 Md. R. 1574)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.01#B" title="">Regulation .01B</a> amended as an emergency provision effective November 18, 2002 (29:24 Md. R. 1912)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.01#B" title="">Regulation .01B</a> amended effective March 3, 2003 (30:4 Md. R. 316)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.01#B" title="">Regulation .01B</a> amended as an emergency provision effective July 1, 2003 (30:15 Md. R. 990); emergency status expired effective January 1, 2004</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.01#B" title="">Regulation .01B</a> amended effective February 16, 2004 (31:3 Md. R. 207); November 23, 2006 (33:23 Md. R. 1794); April 21, 2008 (35:8 Md. R. 805); November 28, 2011 (38:24 Md., R. 1502); September 25, 2017 (44:19 Md. R. 896); December 31, 2018 (45:26 Md. R. 1242)</p>
                  <p>Regulations .01C, N, S; .07F, H; and .09A—C amended effective November 11, 1979 (6:22 Md. R. 1779)</p>
                  <p>Regulation .01E-1—E-3 adopted effective December 26, 1980 (7:26 Md. R. 2422)</p>
                  <p>Regulation .01H-1 amended effective May 5, 1986 (13:9 Md. R. 1029)</p>
                  <p>Regulation .01P amended effective February 8, 1980 (7:3 Md. R. 263)</p>
                  <p>Regulations .02B; .04F (recodified from §H); .05B; .07F-1, H-1 (recodified from §§G and J, respectively) adopted effective November 11, 1979 (6:22 Md. R. 1779)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.03" title=".03 Conditions for Participation.">Regulation .03</a> amended effective March 14, 1989 (16:4 Md. R. 497); November 28, 2011 (38:24 Md., R. 1502); March 31, 2014 (41:6 Md. R. 378); September 25, 2017 (44:19 Md. R. 896)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.03#K" title="">Regulation .03K</a> adopted effective January 6, 1983 (9:26 Md. R. 2572)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.03#L" title="">Regulation .03L</a> adopted effective January 30, 1984 (11:2 Md. R. 113)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.04" title=".04 Covered Services.">Regulation .04</a> amended effective May 1, 1979 (6:7 Md. R. 576); February 8, 1980 (7:3 Md. R. 263); July 11, 1988 (15:14 Md. R. 1654); November 28, 2011 (38:24 Md., R. 1502); June 14, 2021 (48:12 Md. R. 470)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.04#A" title="">Regulation .04A</a> amended effective October 17, 1980 (7:21 Md. R. 1994); July 1, 1989 (16:12 Md. R. 1336); March 19, 1990 (17:5 Md. R. 637); July 1, 1992 (19:12 Md. R. 1134)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.04#A" title="">Regulation .04A</a> amended as an emergency provision effective July 1, 1981 (8:14 Md. R. 1216); adopted permanently effective November 8, 1981 (8:21 Md. R. 1707)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.04#A" title="">Regulation .04A</a> amended as an emergency provision effective January 1, 1982 (8:26 Md. R. 2103); adopted permanently effective April 28, 1982 (9:8 Md. R. 822)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.04#A" title="">Regulation .04A</a> amended as an emergency provision effective November 18, 2002 (29:24 Md. R. 1912)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.04#A" title="">Regulation .04A</a> amended effective March 3, 2003 (30:4 Md. R. 316); February 16, 2004 (31:3 Md. R. 207); September 25, 2017 (44:19 Md. R. 896)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.04#C" title="">Regulation .04C</a> adopted effective March 31, 2025 (52:6 Md. R. 267)</p>
                  <p>Regulation .04E amended effective October 29, 1984 (11:21 Md. R. 1811)</p>
                  <p>Regulation .04G adopted effective March 9, 1987 (14:5 Md. R. 579)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05" title=".05 Limitations.">Regulation .05</a> amended as an emergency provision effective November 18, 2002 (29:24 Md. R. 1912)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05" title=".05 Limitations.">Regulation .05</a> amended effective March 3, 2003 (30:4 Md. R. 316); November 28, 2011 (38:24 Md., R. 1502); September 25, 2017 (44:19 Md. R. 896)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05#A" title="">Regulation .05A</a> amended effective May 1, 1979 (6:7 Md. R. 576); November 11, 1979 (6:22 Md. R. 1779); February 8, 1980 (7:3 Md. R. 263); October 17, 1980 (7:21 Md. R. 1994); October 29, 1984 (11:21 Md. R. 1811); March 9, 1987 (14:5 Md. R. 579); July 11, 1988 (15:14 Md. R. 1654); July 1, 1992 (19:12 Md. R. 1134)</p>
                  <p>Regulations .05A amended as an emergency provision effective July 1, 1981 (8:14 Md. R. 1216); adopted permanently effective November 8, 1981 (8:21 Md. R. 1707)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05#A" title="">Regulation .05A</a> amended as an emergency provision effective January 1, 1982 (8:26 Md. R. 2103); adopted permanently effective April 28, 1982 (9:8 Md. R. 822)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05#A" title="">Regulation .05A</a> amended effective February 16, 2004 (31:3 Md. R. 207); March 13, 2006 (33:5 Md. R. 520); June 14, 2021 (48:12 Md. R. 470); March 31, 2025 (52:6 Md. R. 267)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05#A" title="">Regulation .05A</a>, C amended effective October 22, 2018 (45:21 Md. R. 973)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05#B" title="">Regulation .05B</a> amended effective July 1, 1992 (19:12 Md. R. 1134)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05#C" title="">Regulation .05C</a> amended effective December 26, 1980 (7:26 Md. R. 2422); March 9, 1987 (14:5 Md. R. 579); September 7, 1987 (14:18 Md. R. 1966); July 11, 1988 (15:14 Md. R. 1654); December 12, 1988 (15:24 Md. R. 2769); March 14, 1989 (16:4 Md. R. 497); July 1, 1989 (16:12 Md. R. 1336); March 19, 1990 (17:5 Md. R. 637)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05#C" title="">Regulation .05C</a> amended as an emergency provision effective January 1, 1991 (18:2 Md. R. 145); emergency status expired effective March 31, 1991 (18:8 Md. R. 861)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05#C" title="">Regulation .05C</a> amended as an emergency provision effective July 1, 1992 (19:12 Md. R. 1130); amended permanently effective October 1, 1992 (19:19 Md. R. 1707)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05#C" title="">Regulation .05C</a> amended as an emergency provision effective July 1, 2003 (30:15 Md. R. 990); amended permanently effective November 10, 2003 (30:22 Md. R. 1579)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05#C" title="">Regulation .05C</a> amended effective September 27, 2004 (31:19 Md. R. 1432); August 1, 2005 (32:15 Md. R. 1320); December 6, 2007 (34:24 Md. R. 2157); March 31, 2014 (41:6 Md. R. 378)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05#D" title="">Regulation .05D</a> and E adopted as an emergency provision effective August 30, 1988 (15:20 Md. R. 2331); adopted permanently effective January 1, 1989 (15:24 Md. R. 2769)</p>
                  <p>Regulation .05F and G adopted effective April 21, 2008 (35:8 Md. R. 805)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05-1" title=".05-1 Expanded Limitations.">Regulation .05-1</a> adopted as an emergency provision effective August 18, 1992 (19:18 Md. R. 1653); adopted permanently effective December 1, 1992 (19:23 Md. R. 2040)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.05-1" title=".05-1 Expanded Limitations.">Regulation .05-1</a> amended effective November 28, 2011 (38:24 Md., R. 1502)</p>
                  <p>Regulation .05-1A amended as an emergency provision effective November 18, 2002 (29:24 Md. R. 1912)</p>
                  <p>Regulation .05-1A amended effective March 3, 2003 (30:4 Md. R. 316); September 25, 2017 (44:19 Md. R. 896)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.06" title=".06 Preauthorization Requirements.">Regulation .06</a> amended effective November 11, 1979 (6:22 Md. R. 1779); February 8, 1980 (7:3 Md. R. 263); November 8, 1981 (8:21 Md. R. 1707); August 30, 1982 (9:17 Md. R. 1708); December 19, 1983 (10:25 Md. R. 2268); October 29, 1984 (11:21 Md. R. 1811); September 7, 1987 (14:18 Md. R. 1966); December 12, 1988 (15:24 Md. R. 2769)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.06" title=".06 Preauthorization Requirements.">Regulation .06</a> amended as an emergency provision effective November 18, 2002 (29:24 Md. R. 1912)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.06" title=".06 Preauthorization Requirements.">Regulation .06</a> amended effective March 3, 2003 (30:4 Md. R. 316); November 28, 2011 (38:24 Md., R. 1502); September 25, 2017 (44:19 Md. R. 896)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.06#A" title="">Regulation .06A</a> amended effective July 1, 1992 (19:12 Md. R. 1134); October 10, 2016 (43:20 Md. R. 1109); June 14, 2021 (48:12 Md. R. 470)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.06#A" title="">Regulation .06A</a>, C amended effective December 6, 2007 (34:24 Md. R. 2157)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07" title=".07 Payment Procedures.">Regulation .07</a> amended effective March 14, 1989 (16:4 Md. R. 497); July 1, 1989 (16:12 Md. R. 1336); November 28, 2011 (38:24 Md., R. 1502); September 25, 2017 (44:19 Md. R. 896)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#C" title="">Regulation .07C</a> amended as an emergency provision effective July 1, 1978 (5:14 Md. R. 1131); adopted permanently effective November 3, 1978 (5:22 Md. R. 1673)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#C" title="">Regulation .07C</a> amended effective January 30, 1984 (11:2 Md. R. 113); September 10, 1984 (11:18 Md. R. 1584)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#C" title="">Regulation .07C</a> amended as an emergency provision effective January 1, 1991 (18:2 Md. R. 145); emergency status expired effective March 31, 1991 (18:8 Md. R. 861)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#G" title="">Regulation .07G</a> amended effective June 1, 1985 (12:10 Md. R. 961); May 5, 1986 (13:9 Md. R. 1029); May 4, 1987 (14:9 Md. R. 1080); October 5, 1987 (14:20 Md. R. 2142); April 30, 1988 (15:8 Md. R. 1009); July 11, 1988 (15:14 Md. R. 1654)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#G" title="">Regulation .07G</a> amended as an emergency provision effective August 30, 1988 (15:20 Md. R. 2331); adopted permanently effective January 1, 1989 (15:24 Md. R. 2769)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#H" title="">Regulation .07H</a> amended as an emergency provision effective July 1, 1977 (4:14 Md. R. 1080); emergency status extended at 4:23 Md. R. 1728; adopted permanently effective November 4, 1977 (4:23 Md. R. 1734)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#H" title="">Regulation .07H</a> amended effective July 1, 1978 (5:12 Md. R. 967); May 1, 1979 (6:7 Md. R. 576); July 1, 1980 (7:13 Md. R. 1278); March 9, 1987 (14:5 Md. R. 579); July 1, 1987 (14:13 Md. R. 1473); July 11, 1988 (15:14 Md. R. 1654)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#H" title="">Regulation .07H</a> amended as an emergency provision effective July 2, 1979 (6:14 Md. R. 1204); adopted permanently effective November 2, 1979 (6:22 Md. R. 1779)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#H" title="">Regulation .07H</a> amended as an emergency provision effective July 1, 1982 (9:11 Md. R. 1122); adopted permanently effective November 1, 1982 (9:19 Md. R. 1894)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#H" title="">Regulation .07H</a> amended as an emergency provision effective July 1, 1984 (11:14 Md. R. 1246); adopted permanently effective October 29, 1984 (11:21 Md. R. 1811)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#H" title="">Regulation .07H</a>-1 amended effective March 9, 1987 (14:5 Md. R. 579)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#H" title="">Regulation .07H</a>, I amended effective September 27, 2004 (31:19 Md. R. 1432)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#I" title="">Regulation .07I</a> amended effective March 19, 1990 (17:5 Md. R. 637)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#I" title="">Regulation .07I</a> amended as an emergency provision effective July 30, 1991 (18:17 Md. R. 1911); amended permanently effective October 15, 1991 (18:19 Md. R 2099)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#I" title="">Regulation .07I</a> amended as an emergency provision effective July 1, 1992 (19:12 Md. R. 1130); amended permanently effective October 1, 1992 (19:19 Md. R. 1707)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#I" title="">Regulation .07I</a> amended as an emergency provision effective November 18, 2002 (29:24 Md. R. 1912)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#I" title="">Regulation .07I</a> amended effective March 3, 2003 (30:4 Md. R. 316); June 14, 2021 (48:12 Md. R. 470)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#J" title="">Regulation .07J</a> adopted as an emergency provision effective July 1, 1980 (7:13 Md. R. 1266); adopted permanently effective October 17, 1980 (7:21 Md. R. 1995)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.08#A" title="">Regulation .08A</a> amended effective May 12, 1986 (13:9 Md. R. 1029)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.09#A" title="">Regulation .09A</a>, B amended effective August 17, 1981 (8:16 Md. R. 1365)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.10" title=".10 Appeal Procedures.">Regulation .10</a> amended effective June 6, 1983 (10:11 Md. R. 974); January 24, 2011 (38:2 Md. R. 84)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.11" title=".11 Interpretive Regulation.">Regulation .11</a> adopted effective October 25, 1982 (9:21 Md. R. 2106)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.12" title=".12 Preferred Drug Program.">Regulation .12</a> adopted effective March 3, 2003 (30:4 Md. R. 316)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.12" title=".12 Preferred Drug Program.">Regulation .12</a> amended as an emergency provision effective September 18, 2003 (30:21 Md. R. 1527); amended permanently effective November 10, 2003 (30:22 Md. R. 1580)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.12#E" title="">Regulation .12E</a> amended effective November 23, 2006 (33:23 Md. R. 1794)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.12#G" title="">Regulation .12G</a> amended effective December 6, 2007 (34:24 Md. R. 2157)</p>
                  <p>Table I adopted effective June 1, 1985 (12:10 Md. R. 961)</p>
                  <p>Table I repealed and new Table I adopted effective May 5, 1986 (13:9 Md. R. 1029); amended effective October 5, 1987 (14:20 Md. R. 2142); April 30, 1988 (15:8 Md. R. 1009)</p>
                  <h2>Authority</h2>
                  <p>Health-General Article, §§2-104(b), 15-103, 15-103.1, 15-105, 15-118, and 15-148, Annotated Code of Maryland</p>
                </section>
                <h2 id="/us/md/exec/comar/10.09.03.01" data-order="|10|09|03|.01|" data-ref-path="10|09|03|.01" class="h__section">.01 Definitions.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(1)">(1)</span> "340B price" means the price at which drugs are purchased as authorized under Section 340B of the Public Health Service Act.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(2)">(2)</span> "Actual acquisition cost (AAC)" means the amount paid by a provider for a drug or product less all discounts, rebates, refunds, chargebacks, incentives, and price reductions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(3)">(3)</span> "Allowable cost" means the maximum amount which the Program will reimburse for the drug or product portion of the prescription.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(4)">(4)</span> "Approved unit dose system" means a drug distribution system approved by the Department that is used to prepare and distribute an individual, properly labeled dose of medication for a patient in a nursing facility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(5)">(5)</span> "Brand name drug" means:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(5)(a)">(a)</span> A single source drug;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(5)(b)">(b)</span> An innovator multiple source drug; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(5)(c)">(c)</span> A drug submitted for payment as brand medically necessary.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(6)">(6)</span> "Compounded prescription for intravenous therapy" means a prescription that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(6)(a)">(a)</span> Combines two or more ingredients;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(6)(b)">(b)</span> Is prepared by using aseptic technique under a laminar flow clean bench; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(6)(c)">(c)</span> Is administered to a patient intravenously.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(7)">(7)</span> "Controlled substance" means a drug as defined under 21 U.S.C. §802.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(8)">(8)</span> "Convenience package" means a smaller or specially packaged quantity of a product prepared for the convenience of a patient or provider as opposed to the regular packaging.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(9)">(9)</span> "Copayment" means the amount a participant is liable to pay for prescriptions, when applicable, which is deducted from provider reimbursement.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(10)">(10)</span> "Department" means the Maryland Department of Health, the single State agency designated to administer the Medical Assistance Program under Title XIX, Social Security Act, 42 U.S.C. §1396 et seq.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(11)">(11)</span> "Diluent component" means a liquid used for reconstitution or dilution of an active ingredient in compounded prescription intravenous therapy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(12)">(12)</span> "Direct price" means, for drugs identified by the Program, the price charged by a pharmaceutical manufacturer to a dispensing pharmacy for a product supplied to the pharmacy without intermediate distribution charges, less any rebates, discounts, refunds, chargebacks, incentives, and price reductions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(13)">(13)</span> "Drugs" means legend drugs (those requiring a prescription under federal or State law) or over-the-counter (OTC) drugs (those not requiring a prescription under federal or State law).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(14)">(14)</span> "Early and periodic screening, diagnosis, and treatment (EPSDT)" means a program of preventive health care services for Medical Assistance individuals younger than 21 years old.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(15)">(15)</span> "EPSDT-related service" means diagnosis and treatment necessary to correct or manage health problems detected by a screening performed by a certified EPSDT provider. EPSDT-related services are rendered by a certified EPSDT provider or an appropriate Medical Assistance provider.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(16)">(16)</span> "Family planning services" means providing individuals with the information and means to prevent unwanted pregnancy and maintain reproductive health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(17)">(17)</span> "Federally qualified health center (FQHC)" means an entity as defined by Health-General Article, §24-1301, Annotated Code of Maryland, and §1905(l)(2)(B) of the Social Security Act.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(18)">(18)</span> "Federal supply schedule (FSS)" means the drug pricing program under the collection of multiple award contracts used by federal agencies, U.S. territories, Indian tribes, and other specified entities to purchase supplies and services from outside vendors.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(19)">(19)</span> "Federal upper limit (FUL)" means the upper limit of payment for multiple source drugs for which a specific maximum allowable cost has been established by the Centers for Medicare &amp; Medicaid Services (CMS) of the Department of Health and Human Services pursuant to 42 CFR §447.514.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(20)">(20)</span> "Freestanding clinics" means those clinics, not associated with a hospital, which are under the direction of physicians as further defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.08.01" title=".01 Definitions.">COMAR 10.09.08.01</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(21)">(21)</span> "Generic drug" means a drug that is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(21)(a)">(a)</span> Available to pharmacy providers from at least one manufacturer;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(21)(b)">(b)</span> Rated as therapeutically equivalent by the U.S. Food and Drug Administration; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(21)(c)">(c)</span> Not a brand name drug.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(22)">(22)</span> "Innovator multiple source drug" means a multiple source drug that was originally marketed under an original new drug application approved by the U.S. Food and Drug Administration.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(23)">(23)</span> "Institutional pharmacy" means a pharmacy owned and operated by a hospital, nursing facility, or clinic.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(24)">(24)</span> "Invoice" means:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(24)(a)">(a)</span> A form issued or approved by the Department for use by providers in submitting bills for payment; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(24)(b)">(b)</span> A bill issued by a manufacturer or wholesaler to a provider which indicates proof of purchase and the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(24)(b)(i)">(i)</span> Actual acquisition cost paid by the provider; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(24)(b)(ii)">(ii)</span> The direct price charged to the provider by the manufacturer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)">(25)</span> "Maintenance medication" means medication in chronic therapeutic categories corresponding to the following American Hospital Formulary Service (AHFS) classification numbers:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(a)">(a)</span> Cardiac drugs (24:04);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(b)">(b)</span> Antilipemic agents (24:06);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(c)">(c)</span> Hypotensive agents (24:08);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(d)">(d)</span> Vasodilating agents (24:12);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(e)">(e)</span> Sclerosing agents (24:16);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(f)">(f)</span> Alpha-adrenergic blocking agents (24:20);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(g)">(g)</span> Beta-adrenergic blocking agents (24:24);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(h)">(h)</span> Calcium-channel blocking agents (24:28);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(i)">(i)</span> Renin-angiotensin-aldosterone system inhibitors (24:32);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(j)">(j)</span> Hydantoins (28:12:12);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(k)">(k)</span> Oxazolidinediones (28:12:16);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(l)">(l)</span> Succinimides (28:12:20);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(m)">(m)</span> Anticonvulsants, miscellaneous (28:12:92);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(n)">(n)</span> Replacement solutions (40:12) (potassium supplements only);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(o)">(o)</span> Diuretics (40:28);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(p)">(p)</span> Lipotropic agents (56:24);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(q)">(q)</span> Contraceptives (68:12);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(r)">(r)</span> Estrogens and antiestrogens (68:16);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(s)">(s)</span> Antidiabetic agents (68:20);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(t)">(t)</span> Antihypoglycemic agents (68:22);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(u)">(u)</span> Parathyroid (68:24);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(v)">(v)</span> Progestins (68:32);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(w)">(w)</span> Thyroid and antithyroid agents (68:36);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(x)">(x)</span> Vitamins (88:00);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(y)">(y)</span> Sodium fluoride (92:00); and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(25)(z)">(z)</span> Iron preparations, oral (20.04.04) (oral products in which ferrous sulfate is the only active ingredient and chewable tablets of any ferrous salt if combined with vitamin C, multivitamins, multivitamins and minerals, or other minerals in the formulation).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(26)">(26)</span> "Medical Assistance Program" means a program of comprehensive medical and other health-related care for indigent and medically indigent persons.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(27)">(27)</span> "National average drug acquisition cost (NADAC)" means the average price paid by retail community pharmacies to acquire a prescription or over-the-counter covered out-patient drug as calculated by the Centers for Medicare and Medicaid Services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(28)">(28)</span> "Nominal price" means a price that is less than 10 percent of the average manufacturer price (AMP) in the same quarter for which AMP is computed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(29)">(29)</span> "Nursing facility" means an institution as further defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.10.01#B(30)" title="">COMAR 10.09.10.01B(30)</a>, and classified as a long-term care facility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(30)">(30)</span> "Participant" means a person who is certified as eligible for and is receiving Medical Assistance benefits.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(31)">(31)</span> "Pharmacist" means an individual licensed in good standing to practice pharmacy in the state where the service is provided.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(32)">(32)</span> "Pharmacy" means an establishment or institution licensed in good standing that is required to obtain a permit in accordance with <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 12, Annotated Code of Maryland</a>, or a similar entity legally authorized to dispense legend drugs to the public in the state in which the establishment or institution is located.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(33)">(33)</span> "Pharmacy and Therapeutics Committee" means a committee established by the Department to develop recommendations for pharmacy practices including but not limited to development of a preferred drug list according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.12" title=".12 Preferred Drug Program.">Regulation .12 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(34)">(34)</span> "Preauthorization" means an approval required from the Department or its designee before a drug is dispensed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(35)">(35)</span> "Preferred drug list" means a list of recommended drugs developed by the Department that is based on the recommendations of the Pharmacy and Therapeutics Committee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(36)">(36)</span> "Prescriber" means a physician, dentist, podiatrist, or other professional licensed in good standing to prescribe legend drugs in the state in which the service is provided.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(37)">(37)</span> "Prescription" means an order by a prescriber, or a prescriber’s order transferred from one pharmacist to another, for Program covered pharmacy services in accordance with applicable federal and State laws conveyed in one of the following forms:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(37)(a)">(a)</span> An original order signed by the prescriber and written on tamper-resistant paper which shall contain industry-recognized features designed to prevent:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(37)(a)(i)">(i)</span> Unauthorized copying of a prescription form;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(37)(a)(ii)">(ii)</span> Erasure or modification of information written on the prescription by the prescriber; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(37)(a)(iii)">(iii)</span> Use of counterfeit prescription forms;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(37)(b)">(b)</span> A fax of an original order signed by the prescriber sent directly from the prescriber to the pharmacy provider;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(37)(c)">(c)</span> An electronic order; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(37)(d)">(d)</span> An oral order from the prescriber to the pharmacist if the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(37)(d)(i)">(i)</span> Pharmacist promptly writes or prints out and files the prescription;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(37)(d)(ii)">(ii)</span> Prescription is not for a Schedule II controlled dangerous substance; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(37)(d)(iii)">(iii)</span> Prescription is not for certain drugs that have been determined by the Secretary to present an emerging threat in the State because of increasing abuse and diversion.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(38)">(38)</span> "Professional dispensing fee" means the professional fee as defined in 42 CFR §447.502.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(39)">(39)</span> "Program" means the Maryland Medical Assistance Program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(40)">(40)</span> "Provider" means an individual, association, partnership, or incorporated or unincorporated group of individuals duly licensed or certified to provide services for recipients and who, through appropriate agreement with the Department, has been identified as a Program provider by issuance of an individual account number.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(41)">(41)</span> "Single source drug" means a covered drug which is produced or distributed under an original new drug application approved by the Food and Drug Administration, including a drug product marketed by any cross-licensed producers or distributors operating under the new drug application.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(42)">(42)</span> "State actual acquisition cost (SAAC)" means, for those drugs or products identified by the Program, the Program’s or its designee’s calculation of AAC, based on a survey of providers’ actual prices paid to acquire drugs or products marketed or sold by specific manufacturers, when NADAC is unavailable.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(43)">(43)</span> "State Formulary" means drug products listed in the United States Food and Drug Administration's Current List of Approved Drug Products with Therapeutic Equivalence Evaluations unless disqualified by the Department in conformity with <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=12-504" title="">Health Occupations Article, §12-504, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(44)">(44)</span> "State-only participants" means those participants in the Program administered and financed by the State who do not meet the technical requirements of Title XIX of the Social Security Act and for whom the State does not claim federal financial participation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(45)">(45)</span> "Usual source of supply" means a wholesaler, distributor, or manufacturer from whom pharmacy providers within the State most frequently obtain their pharmaceuticals.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.01#B(46)">(46)</span> "Wholesale acquisition cost (WAC)" means the price pharmaceutical manufacturers and distributors charge to wholesale distributors who provide retail and institutional pharmacies with products used to fill prescriptions.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.02" data-order="|10|09|03|.02|" data-ref-path="10|09|03|.02" class="h__section">.02 License Requirements.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.02#A">A.</span> A pharmacy may not qualify as a provider without first having obtained a permit from the Department pursuant to <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 12, Annotated Code of Maryland</a>, or from the appropriate agency in the state in which the pharmacy is located.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.02#B">B.</span> A pharmacy that provides compounded prescriptions for home intravenous therapy shall be licensed under the provisions of <a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.19" title="Chapter 19 Sterile Pharmaceutical Compounding">COMAR 10.34.19</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.02#C">C.</span> A doctor of medicine or osteopathy shall be licensed and legally authorized to practice medicine and surgery and to dispense drugs in the state in which the service is provided.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.03" data-order="|10|09|03|.03|" data-ref-path="10|09|03|.03" class="h__section">.03 Conditions for Participation.</h2>
                <p>To participate in the Program, the provider shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#A">A.</span> Meet the licensure requirements in <a class="internal-link " href="/us/md/exec/comar/10.09.03.02" title=".02 License Requirements.">Regulation .02 of this chapter</a>;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#B">B.</span> Apply for participation in the Program using the application form designated by the Department;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#C">C.</span> Be approved for participation by the Department;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#D">D.</span> Accept, as payment in full, the amounts paid by the Program plus any copayment required by <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#E">E.</span> Maintain adequate records and prescriptions for a minimum of 6 years, and make them available for inspection, upon request, to the Department or its designee;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#F">F.</span> Ensure that all prescriptions contain sufficient information to justify the invoice charges;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#G">G.</span> Provide services without regard to race, creed, color, age, sex, national origin, marital status, physical or mental handicap;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#H">H.</span> Agree that the provider may not employ knowingly a person who has been disqualified from the Program to compound or dispense Medical Assistance prescriptions, unless prior written approval has been received from the Department;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#I">I.</span> Verify the participant’s eligibility before dispensing covered drugs;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#J">J.</span> Place no restriction on the participant’s right to select providers of the participant’s choice;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#K">K.</span> Agree that if the Program denies payment or requests repayment on the basis that an otherwise covered service was not medically necessary, the provider may not seek payment for that service from the participant;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#L">L.</span> Maintain a record of the individual who picks up a prescription that includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#L(1)">(1)</span> The prescription number;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#L(2)">(2)</span> The name of the individual picking up the prescription;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#L(3)">(3)</span> The signature of the individual picking up the prescription; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#L(4)">(4)</span> The date the prescription was picked up;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#M">M.</span> Reverse invoice charges for any prescription not picked up by the participant or their designee within 14 days;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#N">N.</span> Maintain a record of a participant or designee’s written authorization for automatic refill, if automatic refills are provided;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#O">O.</span> Agree that the provider may not deny services to any participant because of the individual’s inability to pay the copayment;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#P">P.</span> Agree that if the Program denies payment due to late billing, the provider may not seek payment from the participant;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#Q">Q.</span> On the Department’s request, provide within 15 days all invoices, as defined in <a class="internal-link " href="/us/md/exec/comar/10.09.03.01#B(24)(b)" title="">Regulation .01B(24)(b) of this chapter</a>, to assess the AAC; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.03#R">R.</span> Participate in the cost of dispensing survey and, on the Department’s request and within the Department’s timeline, provide to the Department all documentation that the Department or its designee determines is necessary.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.04" data-order="|10|09|03|.04|" data-ref-path="10|09|03|.04" class="h__section">.04 Covered Services.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A">A.</span> The Department shall cover:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(1)">(1)</span> Legend drugs except certain drugs for which federal financial participation is prohibited pursuant to 42 CFR §441.25;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(2)">(2)</span> Schedule V cough preparations;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(3)">(3)</span> Contraceptives;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(4)">(4)</span> Hypodermic needles and syringes;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(5)">(5)</span> Supplemental vitamins and mineral products given by nasogastric, jejunostomy, or gastrostomy tube in the home;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(6)">(6)</span> Enteric coated aspirin when prescribed for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(6)(a)">(a)</span> The treatment of arthritic conditions as certified on the prescription in the prescriber's own handwriting or by the dispenser after consultation with the prescriber; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(6)(b)">(b)</span> At least 250 tablets of 325 milligrams each, whether for initial prescriptions or refills.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(7)">(7)</span> Nonlegend ferrous sulfate oral preparations in the following strengths, dosage forms, and quantities only:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(7)(a)">(a)</span> Drops (125 milligrams per milliliter) in units of 50 milliliter dropper bottles;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(7)(b)">(b)</span> Elixir (220 milligrams per 5 milliliters) in quantities of at least 473 milliliters;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(7)(c)">(c)</span> Syrup (90 milligrams per 5 milliliters) in quantities of at least 473 milliliters; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(7)(d)">(d)</span> Tablets (300 milligrams to 325 milligrams) in quantities of at least 100 tablets;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(8)">(8)</span> Nonlegend chewable tablets of any ferrous salt if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(8)(a)">(a)</span> The tables are combined with vitamin C, multivitamins, multivitamins and minerals, or other minerals;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(8)(b)">(b)</span> The participant is under 12 years old; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(8)(c)">(c)</span> The quantity dispensed is at least 60 tablets and not more than a 100-day supply;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(9)">(9)</span> Nonlegend ergocalciferol liquid (8,000 international units per milliliter); and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#A(10)">(10)</span> Any nonlegend drug determined by the Program to be cost effective.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#B">B.</span> Prescription Requirement.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#B(1)">(1)</span> Except as provided in <a class="internal-link " href="/us/md/exec/comar/10.09.03.04#B(2)" title="">§B(2) of this regulation</a>, a prescription is required for all items to be covered under this regulation even if the item is not a legend drug or otherwise does not require a prescription under federal or State pharmacy law.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#B(2)">(2)</span> A prescription is not required for various forms of latex condoms or other drugs or products identified by the Program, each within the limits established by the Program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#C">C.</span> The Department may cover legend drugs not otherwise covered by <a class="internal-link " href="/us/md/exec/comar/10.09.03.04#A" title="">§A of this regulation</a> when:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#C(1)">(1)</span> The drugs are identified as necessary to address a drug shortage as identified by the United States Food and Drug Administration; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.04#C(2)">(2)</span> The Department determines the coverage of the drugs medically necessary.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.05" data-order="|10|09|03|.05|" data-ref-path="10|09|03|.05" class="h__section">.05 Limitations.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A">A.</span> Except as specifically identified as being covered under <a class="internal-link " href="/us/md/exec/comar/10.09.03.04" title=".04 Covered Services.">Regulation .04 of this chapter</a>, the following are not covered:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(1)">(1)</span> Nonlegend drugs;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(2)">(2)</span> Medical supplies and durable equipment;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(3)">(3)</span> Any original prescription for a controlled substance dispensed more than 30 days after the date it was ordered;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(4)">(4)</span> Drugs supplied to hospital inpatients;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(5)">(5)</span> Drugs and supplies dispensed by the provider with an actual acquisition cost of $0;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(6)">(6)</span> Experimental or investigational drugs;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(7)">(7)</span> Except where authorized by the Department to be covered under this Regulation, injectables dispensed by a provider for administration by the prescriber;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(8)">(8)</span> Food supplements or infant formulas, including supplemental vitamin and mineral products when administered orally;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(9)">(9)</span> Sugar or salt substitutes;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(10)">(10)</span> Cosmetics, medicine chest supplies, and sundries including all soaps, all body powders, all body oils or body lotions, cotton balls, adhesive strip bandages, cotton-tipped applicators, suntan products, deodorants, dentifrices, tissues, convenience packages of covered items, hot water bottles, ice caps, heating pads, soft cervical collars;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(11)">(11)</span> Alcoholic beverages;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(12)">(12)</span> Ostomy supplies;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(13)">(13)</span> Those services authorized for payment to a prescriber, hospital, nursing facility, hospital outpatient department, or freestanding clinic;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(14)">(14)</span> Oral drugs or injections for central nervous system stimulants, anorexigenics, and any other agents when used for weight control;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(15)">(15)</span> Drug products for which federal financial participation is prohibited pursuant to 42 CFR §441.25;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(16)">(16)</span> Ovulation stimulants unless used to treat an iatrogenic infertility;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(17)">(17)</span> Effective January 1, 2006, any Part D drug for individuals who are eligible for Medicare Part D benefits;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(18)">(18)</span> Drugs or products used for hair growth or other cosmetic purposes;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(19)">(19)</span> Any drug or supply that is covered and reimbursed by the Department under any other chapter of this subtitle; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#A(20)">(20)</span> Any drug or product the Department determines is not medically necessary.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#B">B.</span> Prescriptions requiring preauthorization according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.06" title=".06 Preauthorization Requirements.">Regulation .06 of this chapter</a> are not covered unless the required preauthorization has been obtained from the Department or its designee.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C">C.</span> Limitations on Covered Services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(1)">(1)</span> The allowable cost of ingredients dispensed pursuant to a prescription may not exceed an upper limit as established in Regulation .07, of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(2)">(2)</span> Refills.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(2)(a)">(a)</span> The prescriber shall authorize refills only on the original prescription if the prescriber determines a refill is necessary and appropriate.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(2)(b)">(b)</span> The Program may authorize no more than 11 refills, not to exceed other applicable federal and State limitations.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(2)(c)">(c)</span> The pharmacy may not automatically refill a prescription unless authorized in writing by the recipient or their designee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)">(3)</span> Days Supply.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(a)">(a)</span> The total amount dispensed under one prescription order, including refills, is limited to a 360 days supply, not to exceed other applicable federal and State limitations.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(b)">(b)</span> Unless otherwise specified, prescriptions shall be limited to a 34 day supply at one time.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(c)">(c)</span> Unless otherwise specified, maintenance medication shall be limited to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(c)(i)">(i)</span> A 34-day supply for the initial prescription; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(c)(ii)">(ii)</span> Up to a 100-day supply at one time for all subsequent prescriptions.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(d)">(d)</span> Prescriptions shall be dispensed at the lower of the quantity prescribed or the maximum days supply allowed at one time unless:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(d)(i)">(i)</span> The Program authorizes a reduction of the quantity; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(d)(ii)">(ii)</span> The prescription is the final refill for the balance remaining on the total prescription order.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(e)">(e)</span> Providers may partially fill a prescription for Schedule II controlled dangerous substances, but the remaining portion of the prescription may not be later filled.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(f)">(f)</span> Oral sodium fluoride products used in the prevention of dental caries are limited to an original prescription of up to a 120-day supply with up to two refills, not to exceed a total of a 360-day supply.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(g)">(g)</span> Prescriptions for drugs packaged by the manufacturer as an unbreakable unit may be dispensed in increments of appropriate package size.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(3)(h)">(h)</span> Whether for an initial or subsequent prescription, contraceptive prescriptions may be dispensed in up to a 12 months supply at one time.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(4)">(4)</span> Generic Drugs.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(4)(a)">(a)</span> Except as limited by §C(4)(b) and (c) of this regulation, when a drug product is prescribed by its nonproprietary or generic name, a provider shall substitute as follows:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(4)(a)(i)">(i)</span> A drug product in the same strength, quantity, dose, and dosage form as the prescribed drug which is, in the provider’s professional opinion, therapeutically equivalent to the drug as prescribed; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(4)(a)(ii)">(ii)</span> A drug product with the same generic name in the same strength, quantity, dose, and dosage form as the prescribed drug which is, in the provider’s professional opinion, bioequivalent to the drug as prescribed as rated by the U.S. Food and Drug Administration.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(4)(b)">(b)</span> A provider may not substitute a generic drug for a brand name drug under <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(4)(a)" title="">§C(4)(a) of this regulation</a> if:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(4)(b)(i)">(i)</span> The prescriber specifically directs otherwise; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(4)(b)(ii)">(ii)</span> The prescriber requests and received approval from the Program.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(4)(c)">(c)</span> The Department shall only authorize a provider to substitute a drug product under this regulation when there will be a savings in or no increase in cost to the Department.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(5)">(5)</span> Copayment for Services Rendered on or after July 1, 2005.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(5)(a)">(a)</span> There will be no pharmacy copayment for prescriptions for the following:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(5)(a)(i)">(i)</span> Individuals younger than 21 years old;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(5)(a)(ii)">(ii)</span> Pregnant women;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(5)(a)(iii)">(iii)</span> Institutionalized individuals who are inpatients in long-term care facilities or other institutions requiring spending all but a minimal amount of income for medical costs;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(5)(a)(iv)">(iv)</span> Family planning drugs and devices; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(5)(a)(v)">(v)</span> Individuals who are American Indians or Alaskan Natives.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(5)(b)">(b)</span> The copayments for prescriptions not excluded from a copayment under <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)(a)" title="">§C(5)(a) of this regulation</a> are:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(5)(b)(i)">(i)</span> $3 for prescriptions for brand name drugs not on the preferred drug list;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(5)(b)(ii)">(ii)</span> $1 for prescriptions for generic drugs and brand name drugs on the preferred drug list; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(5)(b)(iii)">(iii)</span> $1 for prescriptions for antiretroviral drugs in American Hospital Formulary Service therapeutic class 8:18:08.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(6)">(6)</span> Reimbursement may not be made:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(6)(a)">(a)</span> For nonlegend enteric coated aspirin tablets in strengths other than 300 to 325 milligrams;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(6)(b)">(b)</span> For any other nonlegend aspirin products such as sustained release capsules, buffered tablets, compressed tablets, liquid preparations or combination products in which aspirin is only one of the active ingredients;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(6)(c)">(c)</span> For nonlegend ferrous sulfate products in strengths or dosage forms not listed in <a class="internal-link " href="/us/md/exec/comar/10.09.03.04#A(8)" title="">Regulation .04A(8) of this chapter</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(6)(d)">(d)</span> For nonlegend iron products combined with other active ingredients, except for chewable tablets as described in <a class="internal-link " href="/us/md/exec/comar/10.09.03.04#A(9)" title="">Regulation .04A(9) of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(6)(e)">(e)</span> At a reimbursement level which exceeds the maximum allowable cost established by the Program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(7)">(7)</span> Condoms dispensed by pharmacy providers are subject to the following limitations:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(7)(a)">(a)</span> The recipient shall present a Medical Assistance card with a current eligibility period;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(7)(b)">(b)</span> Only 12 condoms may be dispensed to an individual at one time;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(7)(c)">(c)</span> The provider may dispense condoms only to the individual named on the Medical Assistance card;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(7)(d)">(d)</span> Natural membrane condoms are not covered; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(7)(e)">(e)</span> Both the recipient receiving the condoms and the provider shall sign the dispensing documentation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(8)">(8)</span> A compounded prescription for intravenous therapy is subject to the following limitations:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(8)(a)">(a)</span> The Program may not cover a compounded prescription for intravenous therapy if a premixed, therapeutically equivalent commercial intravenous therapy is available from a commercial source;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(8)(b)">(b)</span> The Program may not cover the diluent component of a compounded prescription for intravenous therapy; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(8)(c)">(c)</span> All claims submitted require new prescription numbers.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(9)">(9)</span> Prescriptions dispensed to participants residing in nursing facilities are subject to the following limitations:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(9)(a)">(a)</span> Claims shall be identified as nursing facilities prescriptions by coding mechanisms determined by the Program;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(9)(b)">(b)</span> Credits for unused unit dose medication and any other medication which may legally be returned to pharmacy stock:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(9)(b)(i)">(i)</span> Shall be made within 60 days of Program payment;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(9)(b)(ii)">(ii)</span> May not take into account any professional fee paid by the Program; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(9)(b)(iii)">(iii)</span> Shall adjust for leave of absence prescriptions; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(9)(c)">(c)</span> Multiple prescriptions dispensed to a recipient residing in a nursing facility for the same drug product or compounded prescription shall receive only one professional fee per calendar month except for:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(9)(c)(i)">(i)</span> Leave of absence prescriptions;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(9)(c)(ii)">(ii)</span> Prescriptions for intravenous therapy; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#C(9)(c)(iii)">(iii)</span> Prescriptions for Schedule II-V controlled substances.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#D">D.</span> Tamper Resistant Prescriptions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#D(1)">(1)</span> Prescriptions written on or after April 1, 2008, that do not contain at least one of the tamper-resistant features as defined in Regulation .01B(34)(a) of this chapter are not covered.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#D(2)">(2)</span> Prescriptions written on or after October 1, 2008, that do not contain all three tamper-resistant features as defined in Regulation .01B(34)(a) of this chapter are not covered.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#E">E.</span> No covered drug or supply identified under <a class="internal-link " href="/us/md/exec/comar/10.09.03.04" title=".04 Covered Services.">Regulation .04 of this chapter</a> shall be reimbursed under <a class="internal-link " href="/us/md/exec/comar/10.09.03.07" title=".07 Payment Procedures.">Regulation .07 of this chapter</a> if:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#E(1)">(1)</span> Federal financial participation from the Centers for Medicare &amp; Medicaid Services is not available for the drug or supply; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05#E(2)">(2)</span> Prior authorization for the drug or supply is required under <a class="internal-link " href="/us/md/exec/comar/10.09.03.06" title=".06 Preauthorization Requirements.">Regulation .06 of this chapter</a> but was not obtained.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.05-1" data-order="|10|09|03|.05-1|" data-ref-path="10|09|03|.05-1" class="h__section">.05-1 Expanded Limitations.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05-1#A">A.</span> A drug is not covered for State-only participants if:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05-1#A(1)">(1)</span> The manufacturer has not provided the same rebate to the State for State-only participants’ purchases of drugs as is required under Section 1927(c) of Title XIX of the Social Security Act (42 U.S.C. §1396r-8(c));</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05-1#A(2)">(2)</span> The Program has provided notice to the manufacturer of the manufacturer's failure to provide adequate rebates and its opportunity to request a waiver from the rebate requirement under <a class="internal-link " href="/us/md/exec/comar/10.09.03.05-1#A(3)" title="">§A(3) of this regulation</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05-1#A(3)">(3)</span> The manufacturer has failed to demonstrate to the Secretary that the drug’s availability is essential to State-Only participants.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.05-1#B">B.</span> A manufacturer or its designee may not dispute or request repayment of any rebate paid under <a class="internal-link " href="/us/md/exec/comar/10.09.03.05-1#A(1)" title="">§A(1) of this regulation</a> or under 42 U.S.C. §1396r-8(c) more than 3 years after the date the rebate was paid.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.06" data-order="|10|09|03|.06|" data-ref-path="10|09|03|.06" class="h__section">.06 Preauthorization Requirements.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A">A.</span> The provider shall obtain preauthorization from the Department or its designee for any prescription for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A(1)">(1)</span> Antibiotic liquids requiring reconstitution for amounts exceeding a 14-day supply;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A(2)">(2)</span> Nonmaintenance drugs for more than a 34 day supply;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A(3)">(3)</span> A usual and customary charge exceeding $2,500;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A(4)">(4)</span> Female hormones for biologic males when used for treating sexual aggression;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A(5)">(5)</span> Vitamin and mineral products when given by nasogastric, jejunostomy, or gastrostomy tube in the home;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A(6)">(6)</span> Drugs rejected by the point-of-sale system because of edits established by the Program to ensure appropriate utilization of medication before the prescription is dispensed, if the Department does not allow provider level overrides;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A(7)">(7)</span> Where a prescriber has filed an official report of an adverse event or product problem with the Program or the United States Food and Drug Administration regarding a generic drug, the brand name drug used as an alternative to that generic drug;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A(8)">(8)</span> Drugs identified by the Program that are subject to fraud or abuse; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A(9)">(9)</span> Drugs not on the preferred drug list developed under <a class="internal-link " href="/us/md/exec/comar/10.09.03.12" title=".12 Preferred Drug Program.">Regulation .12 of this chapter</a> except for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A(9)(a)">(a)</span> Antiretrovirals; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#A(9)(b)">(b)</span> Any other drugs or classes of drugs as determined by the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#B">B.</span> Off-Label Uses of Drugs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#B(1)">(1)</span> The Department may require preauthorization for an off-label use of a drug.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#B(2)">(2)</span> Except as provided in <a class="internal-link " href="/us/md/exec/comar/10.09.03.06#B(3)" title="">§B(3) of this regulation</a>, the Department or its designee may not grant preauthorization for an off-label use of the drug if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#B(2)(a)">(a)</span> The off-label use is inconsistent with generally accepted standards of care;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#B(2)(b)">(b)</span> The drug is prescribed for a non-medically accepted indication;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#B(2)(c)">(c)</span> The drug is prescribed in a manner not approved by the U.S. Food and Drug Administration; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#B(2)(d)">(d)</span> The off-label use is not documented in and supported by the latest edition of:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#B(2)(d)(i)">(i)</span> The American Hospital Formulary Service Drug Information (AHFS-DI);</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#B(2)(d)(ii)">(ii)</span> The Thompson Micromedex Drugdex; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#B(2)(d)(iii)">(iii)</span> The United States Pharmacopeia.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#B(3)">(3)</span> The Department or its designee may grant preauthorization for the off-label use of mental health drugs for individuals 18 years old and younger within the limits established by the Program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#C">C.</span> Preauthorization is not required for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#C(1)">(1)</span> Prescriptions for oral contraceptive drug products;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#C(2)">(2)</span> Drugs dispensed in unit dose form to patients in a nursing facility by a provider using an approved unit dose system.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D">D.</span> Preauthorization Process.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(1)">(1)</span> The provider or the prescriber, if appropriate, ordering a drug subject to preauthorization, shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(1)(a)">(a)</span> Contact the Department or its designee through an established 24-hour hot-line to request preauthorization; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(1)(b)">(b)</span> Provide required information and documentation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(2)">(2)</span> The Department or its designee shall respond to a request for preauthorization by telephone or facsimile request within 24 hours of receipt of a request for preauthorization.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(3)">(3)</span> A 72-hour supply of the prescribed drug shall be allowed:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(3)(a)">(a)</span> In an emergency as determined by the prescriber;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(3)(b)">(b)</span> In an emergency as determined by the pharmacist, if possible in consultation with the prescriber; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(3)(c)">(c)</span> If the Department does not provide a response to a preauthorization request within 24 hours.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(4)">(4)</span> A preauthorization granted by the Department or its designee under this Regulation may not be used by any person as indicating that the individual for whom the prescription was ordered is eligible for Program benefits on the day the prescription is filled or that the Department will guarantee reimbursement for the prescription. All Program restrictions and requirements on eligibility, covered services, and limitations on reimbursement remain in effect.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(5)">(5)</span> A 30-day emergency supply of atypical antipsychotic drugs not on the preferred drug list shall be:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(5)(a)">(a)</span> Immediately authorized by the Department or its designee in an emergency as determined by the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(5)(a)(i)">(i)</span> Prescriber; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(5)(a)(ii)">(ii)</span> Pharmacist, if unable to contact the prescriber; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#D(5)(b)">(b)</span> Limited to a one-time 30-day period.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#E">E.</span> Reconsideration of Adverse Decisions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#E(1)">(1)</span> The Department or its designee shall respond within 48 hours of receiving all necessary documentation of a written request from a participant or provider for reconsideration of an adverse decision on a preauthorization request.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#E(2)">(2)</span> The Department or its designee shall ensure that all adverse decisions of reconsiderations are reviewed and issued by a physician.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#E(3)">(3)</span> Appeals of adverse decisions of reconsideration requests shall be filed in accordance with <a class="internal-link " href="/us/md/exec/comar/10.09.03.10" title=".10 Appeal Procedures.">Regulation .10 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#F">F.</span> The Department or its designee may:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#F(1)">(1)</span> Require preauthorization for more than ten prescriptions including refills per 30-day period per noninstitutionalized participant; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.06#F(2)">(2)</span> May exclude certain drugs such as antibiotics from the limit as appropriate.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.07" data-order="|10|09|03|.07|" data-ref-path="10|09|03|.07" class="h__section">.07 Payment Procedures.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#A">A.</span> The provider shall produce records to verify any charge to the Program upon request.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#B">B.</span> The provider shall bill all appropriate insurance carriers before requesting payment from the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#C">C.</span> Billing time limitations for claims submitted pursuant to this chapter are set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.36" title="Chapter 36 General Medical Assistance Provider Participation Criteria">COMAR 10.09.36</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#D">D.</span> The provider shall submit a request for payment on a form designated by the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#E">E.</span> The Department may return to the provider all invoices not properly completed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#F">F.</span> The pharmacy provider shall charge the Program the provider’s usual and customary charge to the general public for similar prescriptions.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#G">G.</span> The physician or osteopath shall charge the Program his actual acquisition cost for the drugs dispensed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H">H.</span> Determination of Allowable Cost.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(1)">(1)</span> For covered legend drugs and nonlegend drugs, allowable cost shall be:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(1)(a)">(a)</span> The NADAC; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(1)(b)">(b)</span> When the NADAC is unavailable, the lowest of the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(1)(b)(i)">(i)</span> WAC plus 0 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(1)(b)(ii)">(ii)</span> FUL; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(1)(b)(iii)">(iii)</span> SAAC.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(2)">(2)</span> For covered legend brand name drugs for which the prescriber files an official report of an adverse event or product problem regarding a generic drug with the Program or the United States Food and Drug Administration, or when the Department requires the brand name drugs to be dispensed, the allowable cost shall be:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(2)(a)">(a)</span> The NADAC of the branded product; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(2)(b)">(b)</span> When the NADAC of the branded product is unavailable, the lower of the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(2)(b)(i)">(i)</span> WAC plus 0 percent; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(2)(b)(ii)">(ii)</span> SAAC.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(3)">(3)</span> For condoms dispensed by pharmacy providers, the allowable cost shall be as described in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#H(1)" title="">§H(1) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(4)">(4)</span> For covered over-the-counter products, and covered medical supplies, the allowable cost shall be as described in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#H(1)" title="">§H(1) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(5)">(5)</span> For covered specialty drugs not dispensed by a retail community pharmacy but dispensed primarily through the mail, the allowable cost shall be:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(5)(a)">(a)</span> The NADAC; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(5)(b)">(b)</span> When the NADAC is unavailable, the lowest of the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(5)(b)(i)">(i)</span> WAC plus 0 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(5)(b)(ii)">(ii)</span> FUL; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(5)(b)(iii)">(iii)</span> SAAC.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(6)">(6)</span> Except when purchased at the 340B price by a provider, the allowable cost for covered clotting factors shall be the lower of the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(6)(a)">(a)</span> WAC plus 0 percent; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(6)(b)">(b)</span> AAC plus 8 percent.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(7)">(7)</span> For 340B covered entities or FQHCs that fill Program participant prescriptions with drugs purchased at the prices authorized under Section 340B of the Public Health Service Act, the allowable cost shall be the provider’s AAC.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(8)">(8)</span> For facilities that fill Medicaid participant prescriptions with drugs purchased through the FSS, the allowable cost shall be the provider’s AAC.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#H(9)">(9)</span> For facilities that fill Medicaid participant prescriptions with drugs purchased at nominal price, outside of 340B and FSS, the allowable cost shall be the provider’s AAC.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I">I.</span> Payment for Covered Services to a Pharmacy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(1)">(1)</span> Payment for covered legend and nonlegend drugs, over-the-counter products, and covered medical supplies is the lower of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(1)(a)">(a)</span> The provider's charge according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#F" title="">§F of this regulation</a>, less any applicable co-payment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(1)(b)">(b)</span> The amount that is:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(1)(b)(i)">(i)</span> The allowable cost of the item in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#H(1)" title="">§H(1) of this regulation</a>;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(1)(b)(ii)">(ii)</span> Plus the applicable professional dispensing fee indicated in §I(10) or (11) of this regulation; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(1)(b)(iii)">(iii)</span> Less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(2)">(2)</span> Payment for covered legend brand name drugs as indicated in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#H(2)" title="">§H(2) of this regulation</a> shall be the lower of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(2)(a)">(a)</span> The provider’s charge according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#F" title="">§F of this regulation</a>, less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(2)(b)">(b)</span> The total of:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(2)(b)(i)">(i)</span> The allowable cost of the item in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#H(2)" title="">§H(2) of this regulation</a>;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(2)(b)(ii)">(ii)</span> Plus the applicable professional dispensing fee indicated in §I(10) or (11) of this regulation; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(2)(b)(iii)">(iii)</span> Less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(3)">(3)</span> Payment for condoms will be the lower of the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(3)(a)">(a)</span> The provider's charge according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#F" title="">§F of this regulation</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(3)(b)">(b)</span> Allowable cost according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#H(3)" title="">§H(3) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(4)">(4)</span> Copayment is not required for condom orders.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(5)">(5)</span> Payment for covered specialty drugs not dispensed by a retail community pharmacy but dispensed primarily through the mail shall be the lower of the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(5)(a)">(a)</span> Provider charge according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#F" title="">§F of this regulation</a>, less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(5)(b)">(b)</span> The total of:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(5)(b)(i)">(i)</span> The allowable cost of the item in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#H(5)" title="">§H(5) of this regulation</a>;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(5)(b)(ii)">(ii)</span> Plus the applicable professional dispensing fee indicated in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#I(11)" title="">§I(11) of this regulation</a>; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(5)(b)(iii)">(iii)</span> Less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(6)">(6)</span> Payment for clotting factor shall be lower of the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(6)(a)">(a)</span> Provider charge according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#F" title="">§F of this regulation</a>, less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(6)(b)">(b)</span> Amount that is:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(6)(b)(i)">(i)</span> The allowable cost of the item in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#H(6)" title="">§H(6) of this regulation</a>;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(6)(b)(ii)">(ii)</span> Plus the applicable professional dispensing fee indicated in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#I(11)" title="">§I(11) of this regulation</a>; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(6)(b)(iii)">(iii)</span> Less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(7)">(7)</span> Payment for providers that fill Medicaid participant prescriptions with drugs purchased at the prices authorized under Section 340B of the Public Health Service Act shall be the total of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(7)(a)">(a)</span> The allowable cost of the item in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#H(7)" title="">§H(7) of this regulation</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(7)(b)">(b)</span> Plus the applicable professional dispensing fee indicated in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#I(12)" title="">§I(12) of this regulation</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(7)(c)">(c)</span> Less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(8)">(8)</span> Payment for facilities that fill Medicaid participant prescriptions with drugs purchased through the FSS shall be the total of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(8)(a)">(a)</span> The allowable cost of item in §H(8) this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(8)(b)">(b)</span> Plus the applicable professional dispensing fee indicated in §I(10) or (11) of this regulation; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(8)(c)">(c)</span> Less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(9)">(9)</span> Payment for facilities that fill Medicaid participant prescriptions with drugs purchased at nominal price, outside of 340B and FSS, shall be the total of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(9)(a)">(a)</span> The allowable cost of item in §H(9) this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(9)(b)">(b)</span> Plus the applicable professional dispensing fee indicated in §I(10) or (11) of this regulation; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(9)(c)">(c)</span> Less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(10)">(10)</span> The professional dispensing fee for covered services rendered on or after February 1, 2021 to a pharmacy for participants residing in nursing facilities shall be $11.67.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(11)">(11)</span> The professional dispensing fee for covered services rendered on or after February 1, 2021 to a pharmacy for individuals other than residents in nursing facilities shall be $10.67.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(12)">(12)</span> The professional dispensing fee for covered services rendered on or after April 1, 2017 to a pharmacy for medication purchased at the prices authorized under Section 340B of the Public Health Services Act shall be $12.12.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#I(13)">(13)</span> The Department may pay a pharmacy using an approved unit dose system on the basis of a monthly dispensing fee per nursing home resident. The value of the fee may not be higher than the pharmacy’s usual and customary charge to non-Medicaid patients for similar services.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#J">J.</span> Payment for Covered Services to a Physician or Osteopath.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#J(1)">(1)</span> Except as provided in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#J(2)" title="">§J(2) of this regulation</a>, the Program shall reimburse a physician or osteopath for covered drugs dispensed at the lower of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#J(1)(a)">(a)</span> The physician's or osteopath's actual acquisition cost, less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#J(1)(b)">(b)</span> The allowable cost of the item in <a class="internal-link " href="/us/md/exec/comar/10.09.03.07#H" title="">§H of this regulation</a>, less any applicable copayment according to <a class="internal-link " href="/us/md/exec/comar/10.09.03.05#C(5)" title="">Regulation .05C(5) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#J(2)">(2)</span> The Program shall reimburse a physician or osteopath for covered drugs dispensed to Medicaid participants on the same basis as reimbursement to a registered pharmacist if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#J(2)(a)">(a)</span> The physician or osteopath dispenses the covered drugs on a regular basis in the physician's or osteopath’s office;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#J(2)(b)">(b)</span> The physician's or osteopath’s office is not located within a 10-mile radius of a Medicaid participating pharmacy; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#J(2)(c)">(c)</span> The Program, after consultation with the Board of Pharmacy, has verified that the physician or osteopath is dispensing drugs in accordance with accepted pharmacy standards.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.07#K">K.</span> In order to determine whether the current professional dispensing fee is appropriate, the Department will periodically conduct surveys to determine the actual costs involved in filling a prescription in the State.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.08" data-order="|10|09|03|.08|" data-ref-path="10|09|03|.08" class="h__section">.08 Recovery and Reimbursement.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.08#A">A.</span> If the recipient has insurance or other coverage, or if any other person is obligated, either legally or contractually, to pay for, or to reimburse the recipient for services covered by this chapter, the provider shall seek payment from that source first. If an insurance carrier rejects the claim or pays less than the amount allowed by the Medical Assistance Program, the provider may submit a claim to the Program. The provider shall submit a copy of the insurance carrier's notice or remittance advice with his invoice. If payment is made by both the Program and the insurance or other source for the same service, the provider shall refund to the Department, within 60 days of receipt, the amount paid by the Program, or the insurance or third-party source, whichever is less.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.08#B">B.</span> The provider shall reimburse the Department for any overpayment.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.09" data-order="|10|09|03|.09|" data-ref-path="10|09|03|.09" class="h__section">.09 Cause for Suspension or Removal and Imposition of Sanctions.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.09#A">A.</span> If the Department determines that a provider, pharmacist, any agent or employee of the provider, or any person with an ownership interest in the provider has failed to comply with applicable federal or State laws or regulations, the Department may initiate one or more of the following actions against the responsible party:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.09#A(1)">(1)</span> Suspension from Program;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.09#A(2)">(2)</span> Withholding of payment by the Program;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.09#A(3)">(3)</span> Removal from the Program;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.09#A(4)">(4)</span> Disqualification from future participation in the Program, either as a provider or as a person providing services for which Program payment will be claimed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.09#B">B.</span> If the Secretary of Health and Human Services suspends or removes a provider from participation in Medicare, the Department will take similar action.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.09#C">C.</span> The Department may consult with the State Pharmaceutical Association, the State Board of Pharmacy, and the Peer Review Committee of the Medical and Chirurgical Faculty of Maryland. The findings and recommendations of these groups will be given consideration.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.09#D">D.</span> The Department will give the provider reasonable notice of its intentions to impose sanctions. In the written notice, the Department will establish the effective date and the reasons for the proposed action, and advise the provider of the right to appeal.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.09#E">E.</span> Any provider voluntarily withdrawing from the Program or removed or suspended from the Program according to this section shall notify recipients that he no longer honors Medical Assistance cards before rendering additional services.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.10" data-order="|10|09|03|.10|" data-ref-path="10|09|03|.10" class="h__section">.10 Appeal Procedures.</h2>
                <p>Providers filing appeals from administrative decisions made in connection with these regulations shall do so according to <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.36.09" title=".09 Filing Appeal.">COMAR 10.09.36.09</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.11" data-order="|10|09|03|.11|" data-ref-path="10|09|03|.11" class="h__section">.11 Interpretive Regulation.</h2>
                <p>Except when the language of a specific regulation indicates an intent by the Department to provide reimbursement for covered services to Program recipients without regard to the availability of federal financial participation, State regulations shall be interpreted in conformity with applicable federal statutes and regulations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.09.03.12" data-order="|10|09|03|.12|" data-ref-path="10|09|03|.12" class="h__section">.12 Preferred Drug Program.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#A">A.</span> The Department may establish a Pharmacy and Therapeutics Committee (Committee).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#B">B.</span> The Committee shall consist of the following 12 members:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#B(1)">(1)</span> Five members of the Committee shall be Maryland licensed pharmacists residing in the State, including a pharmacist with expertise with mental health drugs;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#B(2)">(2)</span> Five members of the Committee shall be Maryland licensed physicians residing in the State, including a psychiatrist; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#B(3)">(3)</span> Two members of the Committee shall be consumer representatives residing in the State.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#C">C.</span> Consideration for membership on the Committee shall be given to appointing physicians and pharmacists participating in the Program or with experience in developing or practicing under a preferred drug list.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#D">D.</span> The Committee members shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#D(1)">(1)</span> Be appointed by the Secretary;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#D(2)">(2)</span> Have 3 year terms;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#D(3)">(3)</span> Be allowed to serve more than one term; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#D(4)">(4)</span> Elect a chairman and vice chairman.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E">E.</span> The Committee shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E(1)">(1)</span> Meet at least twice a year;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E(2)">(2)</span> To the extent feasible, review all drug classes included on the list at least once every 12 months;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E(3)">(3)</span> Develop recommendations for a preferred drug list for the Program by considering the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E(3)(a)">(a)</span> Clinical efficacy of the drug;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E(3)(b)">(b)</span> Cost effectiveness of the drug, including any supplemental rebates from manufacturers; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E(3)(c)">(c)</span> Needs of Program recipients, such as the ease of drug therapy administration, rate of compliance with drug therapy instructions, and frequency of prior authorization;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E(4)">(4)</span> Recommend:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E(4)(a)">(a)</span> The addition or deletion of existing drugs as necessary;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E(4)(b)">(b)</span> Preauthorization criteria; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E(4)(c)">(c)</span> Conditions or illnesses to be exempted from prior authorization based on clinical data; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#E(5)">(5)</span> Consider medically accepted off-label use of U.S. Food and Drug Administration (FDA) approved drugs.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#F">F.</span> The Department shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#F(1)">(1)</span> Inform the Committee of any decisions regarding the preferred drug list;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#F(2)">(2)</span> Annually publish the preferred drug list;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#F(3)">(3)</span> Maintain an updated preferred drug list that is available electronically;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#F(4)">(4)</span> Ensure, based upon timely notice from the manufacturer, that any new products are reviewed at the next regularly scheduled meeting of the committee;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#F(5)">(5)</span> Provide an expedited review process for newly approved drugs designated as priority by the FDA; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#F(6)">(6)</span> Provide manufacturers and the public an opportunity to submit written material to the committee.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#G">G.</span> The preferred drug list developed by the Department based on the recommendations of the Pharmacy and Therapeutics Committee:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#G(1)">(1)</span> May not include certain therapeutic classes including antiretroviral medications used to treat the AIDS virus, which are exempt from preauthorization as indicated in Regulation .06A(12) of this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#G(2)">(2)</span> Shall, for therapeutic classes other than those described in <a class="internal-link " href="/us/md/exec/comar/10.09.03.12#G(1)" title="">§G(1) of this regulation</a>, include at least one drug approved by the FDA for use in the specific therapeutic class, in every therapeutic class for which the FDA has approved three or fewer drugs for use; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#G(3)">(3)</span> Shall, in every therapeutic class other than those described in <a class="internal-link " href="/us/md/exec/comar/10.09.03.12#G(1)" title="">§G(1) of this regulation</a>, offer a choice of at least two pharmaceutical or biological entities without an administrative preference for each therapeutic class in which there are four or more pharmaceutical or biological entities approved by the FDA.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.09.03.12#H">H.</span> The Department may negotiate and collect supplemental rebates from manufacturers.</p>
                <hr class="section-separator" aria-hidden="true"/>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/10.09.02" aria-label="Chapter 02 Physicians' Services">
                <div class="h__ui">Previous</div>
                <span>Chapter 02 Physicians' Services</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/10.09.04" aria-label="Chapter 04 Home Health Services">
                <div class="h__ui">Next</div>
                <span>Chapter 04 Home Health Services</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
